SB 174 amends Tennessee law to update requirements for surgical assistants seeking board registration. It adds the American Board of Surgical Assistants (ABSA) as an accepted credentialing body alongside the National Commission for Certification of Surgical Assistants, allowing applicants to maintain current ABSA credentials. The bill also removes the December 31, 2019, deadline for applicants to register based on practical experience, making registration more flexible. This change directly affects surgical assistants in Tennessee seeking state licensure, effective March 25, 2025. The law modifies Tennessee Code Annotated § 63-6-219(b)(1) and (b)(3).
HB 584 extends the expiration date of Tennessee's annual limit on new nursing home beds from June 30, 2025, to June 30, 2029. The bill maintains the current cap of 125 new nursing home beds per fiscal year that the Health Facilities Commission can approve through its certificate of need process. This change directly affects nursing home operators seeking to expand their facilities and the commission responsible for reviewing such requests. The bill does not alter the 125-bed limit but only extends the period during which it remains in effect.
HB 1157, the "Restore Trust in Public Health Messaging Act," requires Tennessee's Department of Health, local health departments, and state executive branch to ensure all public communications about FDA-regulated products (like medications) accurately reflect the FDA-approved or FDA-authorized labels. It prohibits promoting information that conflicts with these labels, including general product categories unless universally true or properly qualified. The law mandates an internal compliance review by July 2025, annual reporting to state officials starting in 2026, and a complaint process for violations with potential penalties. This directly affects state health agencies' public messaging about medical products, aiming to align communications with federal FDA standards.
HB 395, the "Tennessee Genomic Security and End Organ Harvesting Act," prohibits Tennessee health insurers from covering organ transplants or post-transplant care if the organ was sourced from China or procured through sale/donation originating in China. It also bans medical and research facilities from using genetic sequencing equipment or software produced by entities linked to "foreign adversaries" (specifically targeting China per the bill's context), requiring replacement within 180 days. Additionally, the bill mandates that all genetic sequencing data must be stored within the United States, with remote access from outside the country prohibited without approval from the state health commissioner. The law takes effect on January 1, 2026, directly affecting health insurers, hospitals, and research facilities operating in Tennessee.
HB 502 expands TennCare coverage to include diagnosis (including genetic testing) and treatment for Kleefstra syndrome, a rare genetic disorder affecting development and multiple body systems. It requires TennCare to provide this coverage in the same manner and extent as for autism spectrum disorder, Down syndrome (Trisomy 21), and other similar genetic disorders, when medically necessary. This applies to all enrolled individuals with Kleefstra syndrome and covers therapies, medications, assistive devices, and interventions aimed at improving quality of life. The law takes effect July 1, 2025, after being signed by the Governor in April 2025.
HB 1201 creates a temporary "foreign training license" for internationally licensed physicians in Tennessee who meet specific criteria. It directly affects physicians trained outside the U.S. but holding valid licenses in their home countries, requiring them to provide proof of an AMA-approved medical education, an ECFMG certificate, three years of postgraduate training (or seven years of practice), and current good standing in their home licensing country. The license is tied to a specific Tennessee healthcare employer, requiring applicants to have a job offer from that provider and restricting practice to that employer unless the board is notified of a change. After two years of active practice in Tennessee under this license, physicians may qualify for a full, unrestricted medical license. The bill takes effect July 1, 2025.
HJR 80 designates May 2025 as "National Hypertension Month" in Tennessee. The resolution urges healthcare providers, insurers, and TennCare to promote hypertension awareness and support coverage for renal denervation therapies, which treat resistant hypertension. It advocates for policy changes to improve access to innovative treatments but does not create new legal requirements. As a symbolic resolution, it encourages state-level action without mandating specific outcomes.
HB 383 requires Tennessee's health commissioner to add alpha-gal syndrome - a rare meat allergy triggered by tick bites - to the state's official list of reportable diseases by July 1, 2025. Healthcare providers must then report diagnosed cases to the Department of Health under existing rules. This bill directly affects medical professionals who will need to submit these reports and public health officials who will track the condition. The law amends Tennessee Code Titles 4, 63, and 68 to implement this change, effective March 26, 2025.
SB 282, the "Individualized Investigational Treatment Act," creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized medical treatments (like gene therapies or vaccines tailored to their genetic profile) when standard FDA-approved options have been exhausted. It directly affects eligible patients (who must meet specific criteria including physician attestation and written informed consent) and eligible facilities (those complying with federal human subjects protections). Key provisions require detailed written consent covering all treatment options, risks, and financial liability, while clarifying that insurers, health plans, and providers are **not obligated** to cover these treatments or related costs (TCA §§ 63-6-1304(a)-(d)). The law takes effect July 1, 2025, and explicitly states that heirs cannot be held liable for unpaid treatment debts if a patient dies during treatment (TCA § 63-6-1305).
This bill adds hepatitis C antibody (anti-HCV) testing to the standard blood screening required for all pregnant women in Tennessee during initial prenatal visits and between weeks 28-32 of pregnancy. If the anti-HCV test is reactive, labs must automatically conduct a follow-up HCV RNA test without requiring additional orders. It directly affects all pregnant women receiving routine prenatal care in Tennessee, expanding the required screening panel to include hepatitis C alongside existing tests for syphilis, rubella, and hepatitis B. The changes take effect July 1, 2025, and align hepatitis C testing protocols with existing disease reporting requirements for maternal health.
